TABLE 1.
Ligands | Cell | EC50 | n |
---|---|---|---|
12-(S)-HETE | CHO/GPR31 | 0.28 ± 1.26 | (n = 6) |
CHO/pcDNA | n.s.b.a | (n = 2) | |
12-(R)-HETE | CHO/GPR31 | n.s.b. | (n = 2) |
CHO/pcDNA | n.s.b. | (n = 2) | |
5-(S)-HETE | CHO/GPR31 | 385.7 ± 62b | (n = 2) |
CHO/pcDNA | n.s.b. | (n = 2) | |
15-(S)-HETE | CHO/GPR31 | 42.1 ± 31b | (n = 2) |
CHO/pcDNA | n.s.b. | (n = 2) | |
12-(S)-HETE | Hela/GPR31 | 0.12 | (n = 1) |
Hela/pcDNA | n.s.b. | (n = 1) | |
12-(S)-HETE | HEK293/GPR31 | 0.11 | (n = 1) |
HEK293/pcDNA | n.s.b. | (n = 1) |
a n.s.b., no specific binding.
b p < 0.05, vs. 12-(S)-HETE-treated CHO/GPR31 cells, t-test.